Abstract For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. Some HTA agencies accept a higher cost per QALY gained when treatment is aimed at prolonging survival for patients with a short expected remaining lifetime, a so-called end-of-life (EoL) premium. The objective of this study is to elicit the existence and size of an EoL premium in cancer. Data was collected from 509 individuals in the Swedish general population 20-80 years old using a web-based questionnaire. Preferences were elicited using subjective risk estimation and the contingent valuation (CV) method. A split-sample design was applied to test for order bias. The mean value of a QALY was MSEK4.8 (€528,000), and there was an EoL premium of 4-10% at 6 months of expected remaining lifetime. Using subjective risk resulted in more robust and valid estimates of the value of a QALY. Order of scenarios did not have a significant impact on the WTP and the result showed scale sensitivity. Our result provides some support for the use of an EoL premium based on individual preferences when expected remaining lifetime is short and below 24 months.
Introduction
For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. The HTA agencies are implicitly placing a monetary value per QALY gained when taking decisions on price or inclusion of the treatment on treatment guidelines. A review of reimbursement decisions by the Swedish Dental and Pharmaceutical Benefits Agency (TLV) shows that the implied willingness to pay (WTP) per QALY is between €80,000 and €135,000 [1] . The TLV does not apply an explicit threshold, and the empirical basis for the maximum WTP per QALY is limited. The value of a statistical life (VSL) applied by the Swedish Transport Administration (€2.64 million [2] ) is, however, used as one reference, which would correspond to a value per QALY of about €106,300
1 [3] . The English equivalent of the TLVthe National Institute for Health and Care Excellence (NICE)-applies an explicit threshold value for a QALY of €25-38,000 (£20-30,000) [4] . The much lower value used & S. Olofsson so@ihe.se by NICE is based on the actual cost per QALY gained in health care (supply side) instead of people's preferences (demand side) [5] . The Cancer Drug Fund (CDF), which was introduced by the UK government in 2011, pays for cancer drugs that have not been reviewed or approved by NICE [6] . The fund implies assigning a higher value to health benefits generated by cancer drugs. The TLV apply a higher threshold to severe diseases (including cancer) [1] , but a number of reimbursement applications for cancer drugs exceeding a cost of €110,000 per QALY gained have been declined [7] [8] [9] . Since the threshold lacks empirical support-other than the implicit reference to the VSL applied in the context of road traffic accidents-it has been questioned whether this corresponds to the value assigned to these gains by the general public [10] . It has also been argued that cancer medicines are associated with factors (e.g., dread, hope) that are not being considered in standard QALY measurements [11] .
The weighting of QALY gains depending on the context in which they appear is an area of debate, and there is both theoretical [12] [13] [14] [15] and empirical support [16] [17] [18] [19] for questioning whether a single value of a QALY is consistent with individual preferences. A review of studies of WTP for a QALY [19] concluded that WTP seems to be higher for life extending QALYs compared to quality of life (QoL) enhancing QALYs. The review also found that WTP for a QALY was negatively related to the size of the QALY gain, which has also been supported in theory [14] . In 2009, NICE implemented end-of-life (EoL) criterion into its decision-making. This meant assigning a higher value to treatments that would cause an increase in survival of 3 months or more for diseases where the expected remaining lifetime was lower than 24 months [20] .
The societal views on a cancer premium and an EoL premium have been assessed in a large-scale study [21] . The study used a choice-based format where respondents were asked to allocate the NHS fund between two different groups of patients. The study showed no preference for giving higher priority to patients with cancer (compared to patients with a non-cancer disease with similar outcome) or to extend life for patients with a short survival time (18 vs. 60 months) . A single comparison of 18 vs. 60 months might, however, not be sufficient to reveal the existence of an EoL premium, since it may still exist for scenarios of shorter expected remaining lifetime (e.g., 6 vs. 60 months).
The existence of an EoL premium has also been assessed in several studies where respondents are asked to choose between treating patient A or patient B who differ with respect to age, length of life, and quality of life before and after treatment. Except for a pilot study of 50 UK respondents [22] , none of the studies have shown more than limited support for an EoL premium [16, 23, 24] .
These studies and the study by Linley and Hughes rely on a social perspective, i.e., stating preferences for others [25] . In a pilot study by Dolan and Green, it was shown that there was a preference for treating someone who is in a less severe health state when using the social perspective even though individuals expressed indifference between treatments for themselves [26] . Studies with a social perspective might therefore not be able to reveal possible preferences for health gains at EoL from the individual perspective, which is considered a valid point of reference according to welfare economics.
The existence of an EoL premium has been assessed using both the patient trade-off (PTO) approach with a social perspective and individual WTP in a study by Pinto Prades et al., finding preference for EoL treatments in comparison to treatments for temporary health conditions [27] . Consistent with the findings of Dolan and Green, the share who preferred treating someone who is less severe was higher when using the social perspective. The share of respondents who did not want to pay anything for the treatment was around twice as high for the more severe health states. This could be a consequence of framing the scenario as certain (ex post), i.e., asking respondents to assume that they were in the severe health state. Some respondents may not want to pay in such a scenario because they feel that it is unethical or would cost more than they can afford. Ex post WTP does not take demand-side uncertainty into account and it is generally considered appropriate to search for the ex ante WTP (i.e., asking respondents to assume they face a risk of the severe health state) in the context of public decision-making for health care programs [28] . GyrdHansen [29] applied an ex ante-based approach by asking respondents to choose one out of four different treatments to include in an insurance policy, varying with respect to age at onset of disease and if treatment was preventive (avoiding onset of disease) or life-extending (EoL). A larger share preferred the preventive treatment. The study, however, did not ask respondents to express their WTP for the treatments and EoL treatments were not compared for different lengths of expected remaining lifetime.
The objective of this study is to estimate the existence and size of an EoL premium in cancer using individual ex ante WTP, enabling individuals to express preferences for themselves and to include risk aversion. This perspective has rarely been used for the purpose of studying EoL preference and could contribute to this research area that has resulted in mixed evidence varying depending on the perspective and elicitation methods used [30, 31] . In contrast to previous studies using this approach, we estimate the existence of an EoL premium by using less extreme comparators and assess if the premium remains when expected remaining lifetime increases. To our knowledge, this is also the first study of an EoL premium and value of a QALY using subjective risk and one of few studies specifying the disease that causes the premature death [32] . A secondary objective is to investigate if there is order bias and scale sensitivity when estimating an EoL premium and to study the characteristics of individuals who have a preference for health gains at EoL.
The rest of the paper is organized as follows. ''Methods'' section describes the study design and presents the details of the methods used. The main result is presented in ''Results'' section and the article ends with a discussion in ''Discussion'' section.
Methods

Study design
The study performs a contingent valuation (CV) study where respondents are asked to state their WTP for an insurance that will give them access to a drug that can prolong survival if they would get a fatal cancer disease during the next 10 years. We constructed a web-based questionnaire presenting four hypothetical scenarios, varying the length of life without treatment and the increase in survival with treatment.
The length of expected remaining lifetime was set based on the length of survival for fatal types of cancer (*6-36 months) and the NICE guidelines (max 24 months for EoL premium). The survival gain was set to represent a reasonable size for existent life-prolonging cancer drugs and to test if there would be an EoL premium at a very short survival gain (3 months). The survival gain was doubled (6 months) to test for scale sensitivity. The scenarios were constructed to test for the existence of an EoL premium (increase of expected remaining lifetime while holding survival gain constant) and scale sensitivity (increase of survival gain while holding expected remaining lifetime constant). Scale sensitivity means that WTP increases close to proportional in relation to the size of the benefit, which is expected according to economic theory [33, 34] .
The questionnaire was distributed to a sample drawn from an Internet panel recruited from a Swedish national population registry. Half of the sample received a questionnaire version with the opposite scenario order to enable a test of order bias.
Questionnaire design and scenario presentation
The first part of the questionnaire included background questions (e.g., sex, age, occupation, income). The respondent was then introduced to the purpose of the study as well as the concept and meaning of WTP. After this, the respondent was introduced to the QoL of a person with a fatal cancer disease on a scale from 0 (representing death) to 100 (representing best possible health) partly based on a review of QoL in cancer 2 [35] and asked to rate her own QoL using the same scale. The respondent was then presented with the risk of dying in cancer. The risk was presented per 1000 persons of the age and sex of the respondent during the next 10 years (Appendix) and illustrated by displaying 1000 dots, whereof X dots were colored black to represent the risk of a fatal cancer disease. The respondent was then asked to estimate her own risk (per 1000 in the next 10 years), to rate impact of cancer risk by own behavior on a scale from 1 (very low or no control) to 5 (high level of control) and to rate worry about getting a fatal cancer disease on a scale from 1 (not worried) to 5 (very worried).
Next, the respondent was asked for her WTP for an insurance, which would give her access to a treatment that could increase length of life if she would get fatal cancer during the next 10 years. The 10-year time horizon was chosen to make the insurance meaningful and baseline risk more tangible. The risk of a fatal cancer disease was presented as the risk estimated by the respondent, i.e., the subjective risk ( Fig. 1 ). Four follow-up sections were included to make it possible for the respondents to review and change their WTP when comparing WTP in different scenarios. The respondents were also asked to choose between two EoL treatments differing with respect to survival without treatment or survival gain to receive a further check on preferences (Table 1) .
After being presented with the WTP scenario, the respondent was shown one amount at a time in numerical order (SEK1/€0.11, 100/11, 500/55, 1000/110, 1500/165, 2000/220, 3000/330, 4000/440, 5000/550, 7000/770, 9000/990 per year) and asked whether she would pay or not pay the amount, a version of the payment card (PC) procedure [36, 37] . The range of amounts were set to identify non-payers and to cover what are assumed to be the range of WTP estimates in this kind of studies [38, 39] . Secondly, the respondent was presented with the highest amount she would pay and the lowest amount she would not pay and asked to state her WTP in an open question.
The respondent was then asked to rate (on a scale from 0 to 10) how sure she was that she would pay the amount if she was given the opportunity to buy the good for that price. This question is assumed to reduce hypothetical bias (i.e., WTP responses deviating from what the respondent would pay for real) [40, 41] . The respondents were also asked to state their reasons for paying or not paying using debriefing questions [36] .
Pilot
The questionnaire was pre-tested by a sample of 53 respondents from an Internet panel and a convenience sample of 14 respondents. The pilot showed that preferences for EoL varied between scenarios and between respondents. To make sure that the order of the scenarios did not cause bias, the final questionnaire was constructed in two versions with opposite scenario order. It was also apparent in the pilot that the increase in survival between scenarios 1-2 (?3 months) and scenarios 3-4 (?12 months) might produce an income effect (i.e., the budget constraint puts a limit on the WTP of the respondent), leading to less reliable estimates. The gain in survival was therefore reduced to ?6 months in scenarios 3-4 in the final questionnaire.
Sample
A web-based version of the questionnaire was programmed and sent to a randomly stratified sample of individuals from You stated earlier that you believe that the risk that you will be diagnosed with a deadly form of cancer within 10 years is [respondent's subjective estimation] in 1,000. Assume that if you fall ill you get a standard treatment, which means you live for 6 months with impaired health before you die.
Also assume that you can buy an insurance today that would give you access to a drug that can prolong your survival by 3 months if you are diagnosed with a deadly form of cancer within 10 years.
The insurance is paid one time per year for ten years.
What is the highest amount you would pay for the insurance? Fig. 1 Example of WTP scenario in EoLQ (timeline was set on 48 months to make scenarios comparable) [29] . There were no differences between samples ( Table 2 ). The respondents were somewhat older, more educated, and had a higher mean income compared to the general population (mean age: 48 [42] ; university education: 34% [43] ; mean household income: *SEK36,000 [44]).
Analysis
Respondents classified as protesters or outliers were excluded in the main analysis. Protesters are identified using debriefing questions and are defined as respondents who do not want to pay because they think the government should pay or respondents who state any WTP because they know they do not have to pay for real [36] . Outliers are defined as respondents stating a WTP in the open-ended question, which is SEK20,000 (€2200) per year or higher. These respondents (QS n = 3-4; QL n = 3-6) were considered outliers since their WTP were found to deviate a lot from the rest of the sample. Respondents rating their own risk as 0 (QS = 4, QL = 5) or 1 (QS = 0, QL = 5) were also considered outliers and excluded, since they did not accept the risk scenario. The main analysis also used the adjusted WTP from the review questions for respondents who wanted to change their WTP. A subgroup analysis was also performed where respondents who rated below 7 on the certainty calibration question were excluded. The cut off at 7 has been supported by previous research [41] , while other studies argue for only treating the respondents rating 10 as certain [39] . WTP is reported in SEK (SEK1 = €0.11).
The value of a QALY (VQALY) for different EoL treatments (e) was calculated by taking the mean of individual ratios derived by multiplying the individual WTP per year by 8.8 (10 years, discounted with 3% [45]) and dividing it by the subjective risk (p) of the individual multiplied by the QALY gain of the treatment (Eq. 1). A similar calculation was also performed to analyze the difference in result from using statistical risk. Since the mean of ratio approach is very sensitive to extreme responses [46] , the result was further trimmed from outliers defined as a value of a QALY above SEK100 million. These respondents (QS n = 1-5; QL n = 2-5) were considered outliers since their value of a QALY can be considered inappropriately high and were found to deviate a lot from the rest of the sample (more than ten times the highest mean).
WTP per year i;e Â 8:
A Wilcoxon signed-ranks test was used to test for significant differences in WTP within groups-i.e., between different scenarios-and a Mann-Whitney U test was used to test for significant differences between groups-i.e., between samples with different scenario orders.
An OLS regression was performed to validate and explain the result, using the log of WTP as the dependent variable and questionnaire version, age, age squared [defined as (age-mean age)^2], sex, university education, log of income per consumption unit [47] , response in certainty calibration, log baseline risk, log subjective risk, control, and anxiety as explanatory variables. The logarithm of WTP and other variables is used to take account of the skewed distribution of WTP and to make the result easy to interpret. Age squared is used to assess if the relationship with WTP takes the form of an inverted U [48] , which is a common finding. The OLS regression was performed for each scenario separately (both questionnaire versions) and for all scenarios pooled.
Results
Risk perception
Mean subjective risk was higher than the mean statistical risk (93 vs. 51 per 1000, p \ 0.001). The tendency to estimate subjective risk above statistical risk was larger when statistical risk was small (Fig. 2) . The majority of respondents rated control of cancer risk (can impact by own behavior) at 3 or above on a five-point scale while the majority of respondents rated worry of cancer death at 3 or below on a five-point scale. There was, however, a significant share of respondents rating control below 3 (29%) and worry above 3 (21%).
Choice-based questions
About 25% of respondents preferred a survival gain of 3 months when expected remaining lifetime was shorter (9 vs. 24 months), i.e., expressing preference for health gains at EoL (Fig. 3 ). An almost equally large share of respondents preferred a survival gain of 3 months when expected lifetime was longer, indicating that preferences regarding health gains at EoL are heterogeneous. About 40% of respondents were indifferent. There was a decline in preference for health gains at EoL when expected remaining lifetime increased from 12 to 21 months (Fig. 3) , but the size of the survival gain did not seem to have much impact on preferences (Fig. 4) . The share of respondents with a preference for health gains at EoL was higher in the questionnaire presenting the shortest survival first (QS), indicating that order has an impact on preferences. Having a university education was associated with a higher probability of preferring a survival gain when expected remaining lifetime is short while worry of cancer death was associated with a lower probability of expressing preferences for health gains at EoL. Although the scenarios were slightly different, about half the sample provided the same preferences in choice-based questions as in WTP.
Willingness to pay (WTP)
The WTP for a survival gain of 3 months was significantly higher when expected remaining lifetime was shorter (6 months vs. 24 months) in QS, indicating the existence of an EoL premium of about 7% (Table 3) . Support for an EoL premium of about 2% was also found in the questionnaire presenting the longest survival first (QL) but the difference was not statistically significant ( Table 4) . The support for an EoL premium seems to be driven by the preferences of women, respondents who are less worried about getting cancer, and respondents who do not believe that they can have much impact on the cancer risk ( Table 5) . The WTP for a survival gain of 6 months was not significantly different when the expected remaining lifetime was shorter (24 months vs. 36 months). This might suggest that an EoL premium only exists when expected remaining lifetime is very short, a finding that is consistent with the result of the choice-based questions.
The WTP for a survival gain of 6 months was significantly higher compared to the WTP for a survival gain of 3 months when expected remaining lifetime was 24 months, indicating scale sensitivity. The difference was close to proportional in QL but less than proportional in QS. There was also evidence for scale sensitivity between samples when comparing QS 24 ? 3 and QL 24 ? 6 (p = 0.0143), but not when comparing QL 24 ? 3 and QS 24 ? 6 (p = 0.1339).
There were no significant differences in WTP between questionnaire versions, indicating no order bias. However, there were different patterns. As stated above, QL resulted in more scale sensitivity and less support for health gains at EoL. The WTP for a 3-month survival gain was also somewhat lower which might be explained by finding it to be of a lower value after having been presented with a 6-month survival gain.
The value of a QALY was between MSEK 3.9 and 5.9 in the main analysis (Fig. 5) , and the mean value of a QALY based on all scenarios and both samples was MSEK 4.8 (95% CI 4.2-5.4). Consistent with the result of the WTP per year, the value of a QALY based on a 3-month survival gain was higher (?4-10%) with a shorter expected remaining lifetime in both versions, although only significantly higher in QS (p = 0.0910). The value of a QALY for scenario 24 ? 6 was lower compared to the value of a QALY for scenario 24 ? 3 in QS (p \ 0.001), while it was higher in QL (p \ 0.001). A possible explanation for this result is that there was less scale sensitivity in QS, and an order effect in QL. The value of a QALY was similar between versions in scenario 24 ? 6 and scenario 36 ? 6 even though these scenarios appeared last in QS and first in QL. When using statistical risk instead of subjective risk in the calculation of the value of a QALY, the estimates and the confidence intervals were larger and the values differed more between versions (Fig. 6 ). Questionnaire version did not have a significant impact on the WTP, indicating no order bias (Table 6 ). Respondents with a university education had a significantly lower WTP compared to respondents without a university education. Income was not related to WTP, which could be a consequence of the negative relation between education and WTP.
Subjective risk was positively related to WTP, as was rating anxiety for cancer above average. This indicates that risk perception is an important driver for the WTP of the respondent, which has also been shown in previous studies. Rating on the certainty scale was positively related to WTP. Age, sex, objective risk, and quality of life were not related to WTP. The WTP in scenario 24 ? 3 was not significantly different from the WTP in scenario 6 ? 3, but the regression coefficient for WTP 24 ? 3 was negative. The WTP in scenario 24 ? 6 and 36 ? 6 were both significantly higher than the WTP in scenario 6 ? 3, indicating scale sensitivity.
Discussion
This is, to our knowledge, one of the first studies using subjective risk and specifying the cause of premature death as cancer when estimating the value of a QALY. It is also one of few studies applying an individual ex ante perspective and split sample with different scenario order to study preferences for health gains at EoL and the value of a QALY. This study shows that the value of a QALY in cancer is around MSEK 4.8 (€528,000) and that there is some support for an EoL premium when the expected remaining lifetime is 6 months. Preference for health gains at EoL was found even though the survival gain was small and the expected remaining lifetime was short in both scenarios. The preference for health gains at EoL also remained after calculating the value of a QALY. However, the support for an EoL premium was reduced when respondents were asked to review their answers and it was not significant when using the opposite scenario order (QL). No support was found for an EoL premium when comparing the value of a 6-month survival gain with 24 and 36 months of expected remaining lifetime. The choice-based questions also reveal a decline in preferences for health gains at EoL when expected remaining lifetime is between 12 and 21 months.
The result of this study is contrary to the study by Linley and Hughes [21] that did not find any support for an EoL premium when using 18 months as the EoL alternative. The results reported here do, however, suggest that support for EoL exists when expected remaining lifetime is very short, and start to decline somewhere between 12 and 21 months. The result of this study is also contrary to the study by Shah et al. [24] that could not show any difference in the preference for a 3-month survival gain depending on the expected remaining lifetime without treatment being 3, 24, or 36 months. One explanation for the difference is that the study by Shah et al. [24] applies a social perspective, which might not reveal individual preferences for a gain in a more severe health state.
Similar to previous research [22, 24, 27] , this study shows that preferences for health gains at EoL are heterogeneous, i.e., the share of respondents who prefer these gains are similar to the share of respondents who prefer health gains at a longer expected remaining lifetime. This study also found that being less worried about getting a fatal cancer illness was associated with preferences for health gains at EoL and more scale sensitivity. A possible explanation for this is that those who are more worried about getting a fatal cancer disease are more concerned about the 'nature of the good' than the magnitude of the good. Avilés Blanco et al. show less sensitivity to scale among respondents who are more afraid or anxious [49] .
This study shows that the value of a QALY in cancer is MSEK 4.8 (€528,000). A review of estimates of the value of a QALY from 21 stated preference studies found a lower mean value of €97,683 [19] . However, it has been argued that this type of study generally produces a lower bound estimate of the value of a QALY since they estimate the WTP for non-marginal changes by applying an ex post perspective [50] . By deriving the value of a QALY from the VSL, it is possible to gain estimates for marginal changes in health using an ex ante perspective, i.e., similar to this study. A VSL of $3-7 million, which is considered reasonable based on both revealed [51] and stated preferences [52, 53] , would imply a value of a QALY between $190,000 and $450,000 [50] . A possible explanation for a higher value of a QALY in this study is the context of cancer, which has been shown to cause dread and consequently of a higher value to avoid it [54] [55] [56] . Viscusi et al. report a VSL of $8.10 million for reducing risk of bladder cancer with a 10-year latency period (period between risk reduction and symptom development) and $10.85 for reducing immediate risk [54] . This would translate to a value of a QALY between $520,714 (€468,643) and $697,500 (€627,750) using the standard approach for deriving the value of a QALY from VSL [50, 57] , which is consistent with this study that uses a self-defined latency period between 0 and 10 years. The share of zeros, protesters, and outliers were similar to what has been reported in other studies [58] , suggesting that respondents who chose to complete the questionnaire did not object to paying for health care to an unusually high degree. In contrast to the study by Pinto Prades et al. [24] , the rate of zero response did not vary much between scenarios and differences are therefore less likely to be driven by zero response. An explanation for the limiting variation in zero response could be the use of an ex ante perspective or that health states were more similar with respect to severity. Subjective risk had a significant impact on WTP, validating the approach and the result of the survey. Consistent with previous research on risk perception, there was found to be a difference between subjective risk and statistical risk. Using the statistical risk to calculate the value of a QALY also resulted in less robust and valid estimates. Bobinac et al. [59] performed an ex ante WTP study to estimate the value of a QALY. The statistical risk was presented to the respondent, and the mean value of a QALY was €250,000 [59] . However, when applying probability weighting to take into account that subjective risk differs from statistical risk, the value decreased to €80,000-€110,000. The value of a QALY reported here is higher, around €528,000. One reason for the higher estimate reported in this study is the context of cancer. Another reason is that the estimates in this study apply to potential survival gains while the study by Bobinac et al. [59] studied potential quality of life gains. It has been shown in previous studies that gains due to an increase in length of life might be valued higher than gains due to enhancing quality of life [14, 19] .
The preference for health gains at EoL when lifetime is short was only significant in QS. A possible reason for this could be that this scenario was presented last in QL. If Questionnaire order long to short (QL) Fig. 5 Mean value of a QALY and 95% CI (bootstrap with 1000 replications) for main sample, using subjective risk (excluding respondents with a value of a QALY above SEK100 million) Questionnaire order long to short (QL) Fig. 6 Mean value of a QALY and 95% CI (bootstrap with 1000 replications) for main sample, using statistical risk (excluding respondents with a value of a QALY above SEK100 million) respondents interpreted payments as cumulative, their budget constraint could have offset a possible EoL premium. It has been found that the first WTP scenario can be used as a reference point for the WTP of subsequent scenarios [60] . Another explanation could therefore be that the lack of an EoL premium at the longer expected remaining lifetime, which was presented first, led to the same response at the shorter expected remaining lifetime. A more proportional increase in WTP in relation to the size of the survival gain was found in QL. Respondents to QS would have to double their previously stated WTP while respondents to QL would have to state half their previously stated WTP in order for a proportional result. The difference in scale sensitivity seems therefore to be a result of an income effect, i.e., the budget of the respondent put a limit on the WTP. This is consistent with results of previous studies suggesting that a top-down design result in more scale sensitivity [61] . The use of an EoL criterion by NICE is supported in this study as well as the application of the criterion when expected remaining lifetime is below 24 months. The current threshold of NICE and the implicit threshold of the Swedish equivalent of NICE, the TLV, is, however, not supported. While the threshold of NICE is primarily based on the actual cost per QALY gained in health care, the TLV applies value-based pricing using a societal perspective. This implies that the value of a QALY should at least include considerations of the preferences of the general population. Reviews on reimbursement decisions by the TLV imply the use of an upper threshold of around MSEK 1 [1] . Several reimbursement applications with a higher threshold have been declined and pharmaceutical companies have consequently started to adapt their applications for this limit. This studyalong with other research-suggests that there are reasons to assume that the general population consider the value of a QALY in the context of cancer treatments with a survival gain to be higher.
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